观察不同剂量辛伐他汀治疗ACS对LP-PLA2及hs-CRP的影响  

Observation of the effect of different doses of simvastatin on LP-PLA2 and hs-CRP during the treatment of ACS

作　　者：冯培峰 赖志斌 邓明玉 FENG Pei-feng, LAI Zhi-bin, DENG Ming-yu(Department of Internal Medicine, Zhaoqing Gaoxin Distritct People＇ s Hospital, Zhaoqing 52623＆ Chin)

机构地区：[1]肇庆市高新区人民医院内科,526238

出　　处：《中国实用医药》2018年第10期1-4,共4页China Practical Medicine

基　　金：广东省肇庆市科技创新计划项目(编号:201624030821)

摘　　要：目的探讨不同剂量辛伐他汀治疗急性冠状动脉综合征(ACS)对患者脂蛋白相关磷脂酶A2(LP-PLA2)及超敏C反应蛋白(hs-CRP)的影响。方法 120例ACS患者,采用数字随机法分为低剂量组、中剂量组和高剂量组,各40例。所有患者均进行常规基础治疗,低剂量组患者另给予10 mg/d辛伐他汀治疗,中剂量组患者给予20 mg/d辛伐他汀治疗,高剂量组患者给予40 mg/d辛伐他汀治疗,比较三组患者治疗前后血脂、LP-PLA2、hs-CRP水平变化情况及用药安全性。结果治疗1、2周后,三组患者甘油三酯、胆固醇、低密度脂蛋白胆固醇水平均低于治疗前,高密度脂蛋白胆固醇水平均高于治疗前,差异有统计学意义(P<0.05)。治疗2周后,高剂量组患者甘油三酯、胆固醇、低密度脂蛋白胆固醇水平均低于中剂量组,中剂量组患者甘油三酯、胆固醇、低密度脂蛋白胆固醇水平均低于低剂量组,差异有统计学意义(P<0.05);中剂量组患者高密度脂蛋白胆固醇水平与高剂量组和低剂量组比较差异无统计学意义(P>0.05)。治疗1、2周后,三组患者LP-PLA2水平均低于治疗前,差异有统计学意义(P<0.05)。治疗2周后,高剂量组患者LP-PLA2水平低于中剂量组,中剂量组患者LP-PLA2水平低于低剂量组,差异均有统计学意义(P<0.05)。治疗1、2周后,三组患者hs-CRP水平均低于治疗前,差异有统计学意义(P<0.05)。治疗2周后,高剂量组患者hs-CRP水平低于中剂量组,中剂量组患者hs-CRP水平低于低剂量组,差异有统计学意义(P<0.05)。治疗2周后,三组患者谷丙转氨酶、谷草转氨酶水平均与治疗前比较差异无统计学意义(P>0.05)。高剂量组患者用药不良反应发生率(2.5%)与低剂量组(0)、中剂量组(0)比较差异无统计学意义(P>0.05)。结论实施辛伐他汀治疗ACS可降低患者LP-PLA2及hs-CRP水平,且实施40 mg/d高剂量治疗效果优于中、低剂量,用药效果及安全性均较高。Objective To discuss the effect of different doses of simvastatin on lipoprotein-associated phospholipase A2 （LP-PLA2） and hypersensitivity C reactive protein （hs-CRP） during the treatment of acute coronary syndrome （ACS）. Methods A total of 120 ACS patients were divided by random number method into low dose group, medium dose group and high dose group, with 40 Cases in each group. All patients were treated with routine basic treatment, and low dose group also treated with simvastatin l^y 10 mg/d, while medium dose group treated with simvastatin by 20 mg/d and high dose group treated with simvastatin by 40 mg/d. The changes of blood lipid, LP-PLA2, hs-CRP and medication safety were compared before and after treatment between the three groups. Results After 1 and 2 weeks of treatment, three groups had lower triglyceride, cholesterol and low density lipoprotein cholesterol than before treatment, and higher high density lipoprotein cholesterol level than before treatment. Their difference was statistically significant （P〈0.05）. After 2 weeks of treatment, high dose group had lower triglyceride, cholesterol and low density liP0protein cholesterol than medium dose group, and medium dose group had lower triglyceride, cholesterol and low density lipoprotein cholesterol. Their difference.was statistically significant （P〈0.05）. Medium dose group had no statistically significant difference in high density lipoprotein cholesterol level comparing with high dose group and low dose group （P〉0.05）. Before treatment, three groups had no statistically significant difference in＇ LP-PLA2 level （P〉0.05）. After 1 and 2 weeks of treatment, three groups had lower LP-PLA2 than before treatment, and the difference was statistically significant （P〈0.05）. After 2 weeks of treatment, high dose group had lower LP-PLA2 level than medium dose group, and medium dose group had lower LP-PLA2 level than low dose group. Their difference was statistically significant （P〈0.05）. After 1 and 2 weeks of

关 键 词：辛伐他汀 急性冠状动脉综合征 血脂 脂蛋白相关磷脂酶A2 超敏C反应蛋白 

分 类 号：R541.4[医药卫生—心血管疾病]